Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Long-Term Experience in a Multi-Centre Study for Adult and Pediatric Patients, on Behalf of GETH-TC
Preprint
- 22 July 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥ 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-centre study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favourable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.Keywords
All Related Versions
- Version 1, 2024-07-22, Research Square
- Published version: Bone Marrow Transplantation, 60 (3), 353.
This publication has 38 references indexed in Scilit:
- Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host diseaseLeukemia Research, 2022
- Ruxolitinib salvage therapy is effective for steroid‐refractory graft‐versus‐host disease in children: A single‐center experiencePediatric Blood & Cancer, 2020
- Ruxolitinib treatment for steroid refractory acute and chronic graft versus host disease in children: Clinical and immunological resultsAmerican Journal of Hematology, 2018
- The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus LeukemiaTransplantation and Cellular Therapy, 2018
- Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant PatientsTransplantation and Cellular Therapy, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group ReportTransplantation and Cellular Therapy, 2006